Since Elevidys' first approval in 2023, experts have been clamoring for more data, particularly in older and non-ambulatory ...

Arrowhead Pharmaceuticals Inc (ARWR) reports robust earnings, strategic partnerships, and pipeline progress, while navigating ...

Q2 2025 Earnings Call Transcript May 12, 2025 Arrowhead Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $2 ...

The Pasadena, Calif., biotechnology company, which uses RNA interference to develop treatments, said Monday it recorded a profit of $370.4 million, or $2.75 a share, during the fiscal second quarter, ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 second quarter ended March 31, 2025. The Company is hosting a conference call today, May 12, 2025, ...

Shares of Sarepta Therapeutics fell after the company cut its full-year outlook, citing significant pressures hurting the broader biotech market. The stock tumbled 21%, to $36.75, in after-hours ...

GlobalData analysts have tipped the global market for genomic therapies to balloon to almost $90 billion by 2030, driven by ...

Sarepta Therapeutics, Inc.’s SRPT share price has surged by 6.43%, which has investors questioning if this is right time to ...

Strong financial performance attributed to the Sarepta license agreement. Positive outlook with multiple product launches anticipated in the coming years. Arrowhead Pharmaceuticals demonstrated a ...

Conference Call and Webcast Today, May 12, 2025, at 4:30 p.m. ET Arrowhead Pharmaceuticals ... the closing last quarter of the agreement with Sarepta Therapeutics, Arrowhead is now funded into ...

Strong financial performance attributed to the Sarepta license agreement. Positive outlook with multiple product launches anticipated in the coming years. Arrowhead Pharmaceuticals demonstrated a ...

Q2 2025 Earnings Conference Call May 12, 2025 4:30 PM ET. Company Participants. Vincent Anzalone - Vice President of Investor Relatio ...